Acute mesenteric venous thrombosis: Improved outcome with early diagnosis and prompt anticoagulation therapy  by Alvi, A. Rehman et al.
lable at ScienceDirect
International Journal of Surgery 7 (2009) 210–213Contents lists avaiInternational Journal of Surgery
journal homepage: www.thei js .comAcute mesenteric venous thrombosis: Improved outcome with early diagnosis
and prompt anticoagulation therapy
A. Rehman Alvi*, Sadaf Khan, Samiullah K. Niazi, M. Ghulam, Shahida Bibi
Department of Surgery, Aga Khan University Hospital, Karachi, Pakistana r t i c l e i n f o
Article history:
Received 29 December 2008
Received in revised form
23 February 2009
Accepted 7 March 2009
Available online 28 March 2009
Keywords:
Acute mesenteric ischemia
Acute mesenteric venous thrombosis
Mesenteric ischemia* Corresponding author. Department of Surgery, A
Stadium Road, P.O. Box 3500, Karachi 74800, Pakistan
E-mail address: rehman.alvi@aku.edu (A.R. Alvi).
1743-9191/$ – see front matter  2009 Surgical Asso
doi:10.1016/j.ijsu.2009.03.002a b s t r a c t
Aim: To analyze the clinical spectrum of acute mesenteric venous thrombosis (AMVT), to assess the
factors affecting the outcome and to determine the optimal management of this disease.
Methods: We retrospectively reviewed the case records of 20 patients with acute mesenteric venous
thrombosis conﬁrmed on CT imaging or on laparotomy over a 23 year period. Patients were divided into
two groups according to the duration of symptoms: group I with symptoms for up to 3 days duration and
group II with symptoms for more than 3 days.
Results: The mean age was 50.55 year, with 15 male and ﬁve female patients. In all patients the diagnosis
were conﬁrmed on CT imaging preoperatively except two patients when the diagnosis was established
on exploratory laparotomy in the period before 1998. There were six patients in group I and 14 in group
II. Five patients underwent an operation and one received a non-operative treatment in group I. Three
patients underwent laparotomy and 11 received non-operative treatment in group II (P-value 0.01,
Fisher’s exact test). There were three and one mortality in groups I (n ¼ 6) and II (n ¼ 14) respectively
(P-value 0.061, Fisher’s exact test). Most patients received preoperative therapeutic anticoagulation. Two
patients in group II who underwent exploratory laparotomy, neither did receive preoperative anti-
coagulation. Both patients died in the postoperative period.
Eighteen patients were investigated for thrombophilia. Eleven patients had one (n ¼ 6) or more (n ¼ 5)
identiﬁable hypercoagulable state, these included protein S deﬁciency (n ¼ 1), both protein C and S
deﬁciency (n ¼ 5), polycythemia (n ¼ 2), factor V Leiden deﬁciency (n ¼ 1) and malignancy (n ¼ 2). None
had antithrombin III deﬁciency, hyperhomocystine urea and contraceptive pill intake. There were no
statistical differences between thrombophilic and non-thrombophilic patients regarding duration of
symptoms, indications for laparotomy and 30 days mortality rate.
Conclusions: Patients with AMVT of rapid onset (<3 days duration) had poor outcome and more patients
required laparotomy because of extensive thrombosis leading to bowel gangrene and peritonitis. Early
diagnosis with CT scanning, prompt treatment with anticoagulation in all patients, surgical treatment in
cases of peritonitis or failure of medical treatment can contain the mortality rate in these patients.
 2009 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Acute mesenteric venous thrombosis (AMVT) is an uncommon
but potentially life threatening type of acute mesenteric ischemia
that comprises 5–15% of all causes.1,2 The ﬁrst description was
made by Elliot in 1895. Warren and Eberhad in 1935 characterized
the clinical entity and identiﬁed poorer the prognosis associated
with it. Abu et al. reviewed 375 cases of AMVT from thega Khan University Hospital,
. Tel.: þ92 21 412 6256.
ciates Ltd. Published by Elsevier Ltinternational literature for the duration between 1911and 1984.
Since then, many studies have explored the etiology, presentation,
diagnostic modalities and therapeutic options of AMVT.2–5 The
diagnosis of AMVT remains mysterious with the condition often
being diagnosed at laparotomy with reported high mortality of
>34%.3–8 The development of high resolution CT scanners have
enabled early detection of the disease and opened new avenues for
management.3,9–12 Early diagnosis and better understanding of the
disease process have enabled clinicians to avert the consequences
of AMVT by appropriate anticoagulation and paved the way for
non-operative management.3,9–13 The policy of early anti-
coagulation in all patients and surgical intervention in selective
cases has produced a reduction in mortality in these patients. Thed. All rights reserved.
Fig. 1. Double Contrast CT Scan shows thrombosis of portal vein and IVC.
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unknown and a search of the literature does not reveal any study
related to AMVT from this country. The aim of the present study
was to analyze the clinical spectrum, assess the factors affecting the
outcome and determine the optimal management of this disease.
2. Materials and methods
2.1. Patients and study design
This was an observational case series over a period of 23 years
from 1984 to 2007 and involved 20 consecutive patients with
diagnosis of acute mesenteric venous thrombosis established by
CT scanning or at operation. During the period from 1984 to 2001,
two patients were diagnosed with AMVT. The diagnosis was
established at laparotomy. The remaining 18 patients were diag-
nosed during the period from 2002 to 2007. Their diagnosis was
established on CT scanning. The ﬁles were retrieved through ICD
10 coding system and included all adult patients (16 years of age)
with the ﬁnal diagnosis of acute AMVT. Study Performa was
designed and 441 ﬁles were reviewed. Four patients with AMVT
were excluded because of missing or incomplete medical records.
From 1984 to 2001 more than 400 medical records were reviewed
with the intraoperative diagnosis of bowel ischemia and gangrene.
However, only two patients had clearly deﬁned AMVT with
normal mesenteric arteries at surgery and so were included in the
analysis.
2.2. Methods
The datawas gathered on a Performa from the review of medical
records and the information was coded and entered in a database
created on software SPSS-14. The variables included were: demo-
graphics, clinical features, duration, laboratory investigations,
radiological imaging, risk factors, associated medical conditions,
management and treatment outcome. The patients were classiﬁed
into two groups based on duration of symptoms: group I included
patients with symptoms for up to 3 days and group II included
patients with duration of symptoms was more than 3 days.
2.3. Statistical analysis
Statistical analysis was done on software SPSS-14. Frequency
tables were generated for variables with the calculation of their
means and ranges. Chi-square and Student’s t-test, Fisher’s exact
test and Mann–Whitney U-test were applied to identify the
differences between different groups and was considered signiﬁ-
cant if P-value was <0.05.
3. Results
3.1. Clinical data of the patients
Twenty patients with acute superior mesenteric venous
thrombosis (AMVT) were managed at this institution over a period
of 23 years. The mean age at diagnosis was 50.55 years (range 40–
90), with 15 men and ﬁve women. The diagnosis of AMVT was
established by a positive CT scan (Fig. 1) in all 18 patients presented
after 2001. Two patients that presented before the year 2001 had
their diagnosis conﬁrmed on exploratory laparotomy.
3.2. Etiology of hypercoagulable state
Of the 18 patients who underwent investigation, 11 had one
(n ¼ 6) or more (n ¼ 5) identiﬁable hypercoagulable states. Theseincluded protein S deﬁciency (n ¼ 1), both protein C and S deﬁ-
ciency (n ¼ 5), polycythemia (n ¼ 2), factor V Leiden deﬁciency
(n ¼ 1) and malignancy (n ¼ 2). None had antithrombin III deﬁ-
ciency, hyperhomocystine urea or history of oral contraceptive use.
Two patients died within 48 h of admission and could not be
investigated for hypercoagulable state.
Statistical analysis was done to identify the differences between
thrombophilic and non-thrombophilic patients. There was no
difference in duration of symptoms (P-value 0.87, Mann–Whitney
U-test), indications for laparotomy (P-value 0.39, Fisher’s exact test)
and 30 day mortality rate (P-value 0.56, Fisher’s exact test). All
patients had associated co-morbid conditions. These included
diabetes mellitus (n ¼ 6), hypertension (n ¼ 5), cigarette smoking
(n ¼ 5), chronic liver disease (n ¼ 2) and malignancy (n ¼ 2).
3.3. Anatomy of vessel involvement
CT scanning was performed in 18 patients at admission,
including four patients in group I and all 14 patients from group II.
The vessels found to be involved on CT scan were as follows:
superior mesenteric vein (SMV, n ¼ 18), portal vein (n ¼ 10),
splenic vein (n ¼ 6) and two patients had inferior vena cava
thrombosis with SMV and PV thrombosis.
3.4. Treatment group
Treatment was based on clinical presentation and condition of
the patient. All patients in this study group had an acute mesenteric
venous thrombosis with less than 2 weeks duration. After resus-
citation and supportive care, therapeutic heparinization was
started with 10,000 units’ intravenous bolus and then continuous
infusion to maintain APTT between 2.5 to 3 times the normal
values. Heparin infusion was continued during surgery and the
postoperative period. The patients were anticoagulated with oral
warfarin prior to discharge.
The clinical features of AMVT are listed in Table 1. The most
common presenting symptoms were abdominal pain, vomiting and
diarrhea. Most patients were dehydrated with tachycardia,
abdominal tenderness. Six patients had signs of peritonitis. There
were no signiﬁcant differences in clinical presentation of patients
treated non-operatively and those requiring surgery. Eight patients
required surgery and laparotomy was done within 12 h of admis-
sion for peritonitis. Additionally, two patients underwent surgery
when their clinical condition deteriorated despite 48–72 h of
anticoagulation therapy. One patient with early signs of peritoneal
Table 1
Clinical features of AMVT.
Features No of
patients
(n ¼ 20)
Medical
management
(n ¼ 12)
Surgical
management
(n ¼ 8)
P-value
Abdominal pain 20 12 8 0.675
Vomiting 6 2 4 0.386
Diarrhea 5 2 3 0.643
Tachycardia
(pulse >100/mint
9 4 5 0.199
Fever (Temp >38 C) 2 2 0 0.093
Leucocytosis
(WBC >1200/l)
9 3 6 0.142
Abdominal tenderness 17 11 6 0.648
Absent bowel sounds 12 6 6 0.183
Metabolic acidosis
(pH <7.2)
3 1 2 0.396
P-value calculated by Chi-square.
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Comparative analysis of groups I and II patients was done to
calculate the statistical differences regarding: survival, required
surgical intervention, length of hospital stay and the 30 day
mortality rate (Table 2). Patients in group I (n ¼ 6) had a poorer
prognosis with regards to improvement with operative and non-
operative treatment (P-value 0.061, Fisher’s exact test). They had
a higher 30 daymortality rate of 50% (n ¼ 3) (P-value 0.061, Fisher’s
exact test) and the majority of patients (n ¼ 5) required laparotomy
(P-value 0.01, Fisher’s exact test) within 12 h of hospital admission.
Of the ﬁve patients in group I who underwent laparotomy, three
received preoperative anticoagulation therapy. In this sub-group,
one patient died. Two patients did not receive preoperative anti-
coagulation treatment and both died postoperatively.
In group II (n ¼ 14) all patients received anticoagulation. Three
patients required laparotomy. Indication for surgery was develop-
ment of peritonitis within 24 h in one patient and no demonstrable
improvement after 48–72 h of anticoagulation therapy in two
patients. Two of the three patients that required surgery did well.
One patient died due to a massive myocardial infarction. Eight
patients in groups I and II that required surgery, three patients had
small bowel perforation and ﬁve patients had small bowel
gangrene. Five patients underwent small bowel resection with
primary anastomosis. In three patients, bowel resection and ileos-
tomy was performed.
3.5. Clinical course and follow up
Over a 23 year period, 20 cases of AMVT were managed at this
institution. Twelve patients were treated with anticoagulation
alone with positive outcome (and one patient died of myocardial
infarction. Eight patients required surgery and six patients under-
went laparotomy with in 12 h of admission due to peritonitis and
two more patients required surgery over 24–72 h ofTable 2
Comparison of outcomes in patients according to duration of symptoms.
Outcome Up to 3 days >3 days (n ¼ 6) P-value (n ¼ 14)
Required surgery 5 3 0.018y
Survival 3 13 0.061y
Length of stayU 6  4 8  7 0.239z
Mortality* 3 1 0.061y
y Fisher’s exact test.
z Mann–Whitney U-test.
U Median days  IQR.
* 30 day mortality.anticoagulation therapy. We noted a poor outcome in patients
when the duration of symptoms was up to 3 days (group I) as
compared to those patients who presented with more than 3 days
of symptoms (group II). More patients in group I required surgery
(P-value 0.01) with a higher mortality rate (P-value 0.061).
The mean hospital stay in group I patients was 4  20 days and
8  7 days in group II patients (P-value 0.239, Mann–Whitney U-
test). The average follow up was 6 months in non-surgical and
45 months in surgically treated patients. All the patients were
continued on oral anticoagulation (Warfarin sodium) and INR was
maintained between 2.5 and 3. Anticoagulant was continued for
6 months in non-thrombophilic (idiopathic) AMVT and was
continued lifelong in thrombophilic patients. There was no recur-
rence of symptoms, readmission or mortality recorded during the
follow up period.
4. Discussion
Acute mesenteric venous thrombosis remained a diagnostic
dilemma for decades. Consequently, the true incidence of this
condition is unknown. AMVT is certainly a rare but distinct clinical
entity which should not be confused with other causes of mesen-
teric ischemia. AMVT is responsible for 1.5–15% cases of mesenteric
ischemia.2–5
This study describes patient outcome in a single center series of
patients with acute mesenteric venous thrombosis. This case series
and other reports7–10 shows that the number of patients with non-
thrombophilic AMVTcontinues to decrease with increased facilities
to recognize hypercoagulable state. An apparent increase of AMVT
as we have experienced over the past 7 year may be due to
improved radiological imaging and high resolution angiography
facilities. This is also experienced by other centers worldwide.3,9–11
From 1984 to 2001, we identiﬁed two patients with AMVT on
laparotomy for peritonitis. Both patients did not receive preoper-
ative anticoagulation and both had a poor outcome. Between 2002
and 2007, we diagnosed 18 patients with AMVT on contrast
enhanced CT scanning. All received early anticoagulation therapy
with a positive outcome in terms of more survival and a lesser
number of patients requiring surgery.
The most important observation in this study was duration of
symptoms before hospital admission. This signiﬁcantly inﬂuenced
the outcome in patients with AMVT including survival, mortality
and need for laparotomy. Patients who had symptoms of up to
3 days duration (group I) had poor outcome. More patients (83%)
required laparotomy as compared to group II, of which one patient
(20%) underwent laparotomy (P-value 0.018). The mortality in
group I patients were much higher (50%) as compared to group II
patients (7%) with P-value of 0.06. Duration of symptoms and the
time from presentation to conﬁrm the diagnosis of AMVT greatly
inﬂuenced the management plan in this case series. All except one
patient in group I underwent laparotomy within 12 h of admission
because of generalized peritonitis. Two of the patients in this group
underwent laparotomy without preoperative anticoagulation with
a poor outcome as compared to the other three patients. This group
with a more acute presentation (group I) indicates patients with
extensive thrombosis leading to bowel gangrene and peritonitis
and has been reported by other investigators.16,17 Patients with less
acute presentation (group II) were more stable during the course of
their illness. The extent of thrombosis was probably less. More
patients (80%) were treated non-operatively (anticoagulation) with
positive outcome. This observation is also noted in the existing
literature.1–5
Our series shows that non-operative therapy is an option when
the diagnosis is made on CT imaging in a patient without signs of
peritonitis. Bowel ischemia due to AMVT is a reversible process
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enhanced CT could allow a substantial number of patients to be
treated non-operatively with reversal of bowel ischemia.9 Reports
suggest that early anticoagulant therapy improves outcome in both
medical and surgical treated patients.7,9–12
Our protocol to continue oral anticoagulant for 6 months in
primary and lifelong therapy in secondary AMVT has proven to be
effective with no recurrence on follow up visits. The current
evidence supports the protocol of close follow up with mainte-
nance of oral anticoagulation therapy to keep the INR in the range
of 2.5–3 to avoid recurrence.9–12 Eighteen patients were investi-
gated for hypercoagulable state and 61% (n ¼ 11) were found to
have underlying cause for AMVT. Six patients had single and ﬁve
had more than one factor positive. The most common factors were
protein C and S deﬁciencies and myeloproliferative disorder. The
literature has reported similar results of secondary AMVT.8,10–12 In
this series, we have done a comparative analysis of patients with
and without thrombophilic states and found no differences in
clinical presentation (P-value 0.87), indication for laparotomy (P-
value 0.39) and mortality rate (P-value 0.56). Other investigators
have not been able to prove that non-thrombophilic (primary)
AMVT is a separate clinical entity although about 40% of AMVT
occurs without obvious cause.5–10
5. Conclusion
In conclusion, acute mesenteric venous thrombosis must be
considered a possible diagnosis with abdominal pain out of
proportion to physical ﬁndings. Early CT imaging allows for
immediate anticoagulation and seems to improve outcome. Acute
presentation of up to 3 days duration has a poor outcome. The
majority of these patients required laparotomy because of gener-
alized peritonitis. The outcome was dismal when diagnosis was
established on laparotomy with patients not receiving pre and
intraoperative anticoagulation therapy. The majority of patients
with less acute presentation (>3 days) were treated non-opera-
tively with better survival and mortality rates.
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